We are excited to showcase our AI project with @uniQure_NV. In our latest blogpost, we describe how we collaborated with @uniQure_NV to build an automated image analysis pipeline, that enables uniQure to determine the localisation of their gene therapy candidates ~45x faster

DeepMirror has been awarded UKRI’s “Innovative technologies for nucleic acid medicines manufacturing” grant in collaboration with BiologIC Technologies. deepmirror.ai/post/deepmirro…

From 2001 to 2020, big pharma companies developed and launched 251 drugs (about half of all FDA approved drugs in that period), spending a staggering $6.16 Billion per drug approval. forbes.com/sites/alexzhavoro…

Small molecules are increasingly complex owing to incredible advances in chemistry. Yet a rise in drug complexity is also reflective of the mounting challenges in finding drugs that are truly impactful. (1/5) drughunter.com/small-molecul…

More complex drugs means better therapies but it also means longer and harder development. It took 16 years to move Lenapacavir from research lab to FDA approval. (4/5)

Earlier this month, nature published a great birds-eye-view introduction into AI in drug discovery: nature.com/articles/s41591-0… Charles Mowbray (discovery director at DNDi), shares what we agree is the greatest strength of AI in science (a thread):

"These [AI] tools don’t replace a scientist, they complement them." [AI] enables them to have all the information at their fingertips, to ask the good questions, to refine their queries, and to iterate until they can figure out what they’re really after.”